Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative serplulimab plus SOX/CapOX versus SOX/CapOX for locally advanced intestinal or mixed-type gastric/GEJ adenocarcinoma
ChiCTR2400086120Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serplulimab, oxaliplatin, tegafur and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Complete pathological response and Event-free survival. Started Jul 2024; status: recruiting.
02
Drugs
serplulimaboxaliplatintegafurcapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400086120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086120.